PRDS News and Press, Pardes Biosciences Inc. From 01/31/23

This week could bring some fluctuations to the stock market. Whether you’re investing in penny stocks or more expensive shares, several key factors will shape the year’s first quarter. Economic data releases, earnings announcements, and the highly anticipated January FOMC meeting ar...

Pardes Biosciences press release ( NASDAQ: PRDS ): Q3 GAAP EPS of -$0.40 beats by $0.08 . Pardes’ cash and cash equivalents as of September 30, 2022, were $209.1 million compared to $228.6 million as of June 30, 2022. For further details see: Pardes Bi...

CARLSBAD, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug candidate for the treatment and prevention of COVID-19 in adult and pediatric patients, today ...

CARLSBAD, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections...

CARLSBAD, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and COVID-19...

Pardes Biosciences ( NASDAQ: PRDS ) said it began a phase 2 trial of oral drug PBI-0451 to treat non-hospitalized symptomatic adults with COVID-19 who are not at increased risk of progressing to severe illness. The company expects to enroll 210 patients in the study&#x...

Phase 2 trial expected to enroll 210 patients at approximately 75 sites to evaluate antiviral activity, safety, and efficacy of PBI-0451 versus placebo Interim data from Phase 2 anticipated in Q1 2023 CARLSBAD, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences,...

CARLSBAD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infectio...

Pardes Biosciences press release ( NASDAQ: PRDS ): Q2 GAAP EPS of -$0.48. Pardes’ cash and cash equivalents as of June 30, 2022, were $228.6M compared to $247.9M as of March 31, 2022. The company expects that the cash and cash equivalents it had on hand as of J...

CARLSBAD, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and COVID-19 disease, toda...